Journal of Internal Medicine Concepts & Practice >
Research progress of cardiovascular damage in primary aldosteronism
KE Yuya, GONG Yanchun . Research progress of cardiovascular damage in primary aldosteronism[J]. Journal of Internal Medicine Concepts & Practice, 2023 , 18(04) : 301 -304 . DOI: 10.16138/j.1673-6087.2023.04.019
| [1] | Haze T, Hirawa N, Yano Y, et al. Association of aldo-sterone and blood pressure with the risk for cardiovascular events after treatments in primary aldosteronism[J]. Atherosclerosis, 2021, 324: 84-90. |
| [2] | Hundemer GL, Vaidya A. Primary aldosteronism diagnosis and management[J]. Endocrinol Metab Clin North Am, 2019, 48(4): 681-700. |
| [3] | Monticone S, Sconfienza E, D’Ascenzo F, et al. Renal damage in primary aldosteronism: a systematic review and meta-analysis[J]. J Hypertens, 2020, 38(1): 3-12. |
| [4] | Conn JW, Louis LH. Primary aldosteronism, a new clinical entity[J]. Ann Intern Med, 1956, 44(1): 1-15. |
| [5] | Cheng CJ, Sung CC, Wu ST, et al. Novel KCNJ5 mutations in sporadic aldosterone-producing adenoma reduce Kir3.4 membrane abundance[J]. J Clin Endocrinol Metab, 2015, 100(1): E155-E163. |
| [6] | Fernandes-Rosa FL, Daniil G, Orozco IJ, et al. A gain-of-function mutation in the CLCN2 chloride channel gene causes primary aldosteronism[J]. Nat Genet, 2018, 50(3): 355-361. |
| [7] | Perez-Rivas LG, Williams TA, Reincke M. Inherited forms of primary hyperaldosteronism: new genes, new phenotypes and proposition of a new classification[J]. Exp Clin Endocrinol Diabetes, 2019, 127(2/3): 93-99. |
| [8] | Daniil G, Fernandes-Rosa FL, Chemin J, et al. CACNA1H mutations are associated with different forms of primary aldosteronism[J]. EBioMedicine, 2016, 13: 225-236. |
| [9] | Fernandes-Rosa FL, Giscos-Douriez I, Amar L, et al. Different somatic mutations in multinodular adrenals with aldosterone-producing adenoma[J]. Hypertension, 2015, 66(5): 1014-1022. |
| [10] | Nishimoto K, Tomlins SA, Kuick R, et al. Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands[J]. Proc Natl Acad Sci U S A, 2015, 112(33): E4591-E4599. |
| [11] | Wannachalee T, Turcu AF. Primary aldosteronism: a continuum from normotension to hypertension[J]. Curr Cardiol Rep, 2021, 23(8): 105. |
| [12] | Abdel Ghafar MT. An overview of the classical and tissue-derived renin-angiotensin-aldosterone system and its genetic polymorphisms in essential hypertension[J]. Steroids, 2020, 163: 108701. |
| [13] | Gao X, Yamazaki Y, Tezuka Y, et al. Pathology of aldo-sterone biosynthesis and its action[J]. Tohoku J Exp Med, 2021, 254(1): 1-15. |
| [14] | van der Heijden CDCC, Smeets EMM, Aarntzen EHJG, et al. Arterial wall inflammation and increased hematopoietic activity in patients with primary aldosteronism[J]. J Clin Endocrinol Metab, 2020, 105(5): E1967-E1980. |
| [15] | Rossi GP, Maiolino G. Excess arterial damage in hyperaldosteronism[J]. Hypertension, 2019, 74 (3): 502-504. |
| [16] | Monticone S, D’Ascenzo F, Moretti C, et al. Cardiovascular events and target organ damage in primary aldo-steronism compared with essential hypertension: a systematic review and meta-analysis[J]. Lancet Diabetes Endocrinol, 2018, 6(1): 41-50. |
| [17] | Ohno Y, Sone M, Inagaki N, et al. Prevalence of cardiovascular disease and its risk factors in primary aldosteronism[J]. Hypertension, 2018, 71(3): 530-537. |
| [18] | Sukor N. Primary aldosteronism: from bench to bedside[J]. Endocrine, 2012, 41(1): 31-39. |
| [19] | Meng Z, Dai Z, Huang K, et al. Long-term mortality for patients of primary aldosteronism compared with essential hypertension[J]. Front Endocrinol (Lausanne), 2020, 11: 121. |
| [20] | Andrea Grillo, Lucia Salvi, Coruzzi P, et al. Sodium intake and hypertension[J]. Nutrients, 2019, 11(9): 1970. |
| [21] | Kronenberg H, Melmed S, Polonsky K, et al. Williams textbook of endocrinology[M]. 11th ed. Philadelphia, PA: Saunders, 2007: 1452-1463. |
| [22] | Sang M, Fu Y, Wei C, et al. Comparison of biomarkers of endothelial dysfunction and microvascular endothelial function in patients with primary aldosteronism and essential hypertension[J]. J Renin Angiotensin Aldosterone Syst, 2021, 22(1): 1470320321999491. |
| [23] | Concistrè A, Petramala L, Bonvicini M, et al. Comparisons of skin microvascular changes in patients with primary aldosteronism and essential hypertension[J]. Hypertens Res, 2020, 43(11): 1222-1230. |
| [24] | Lottspeich C, K?hler A, Czihal M, et al. Atherosclerotic burden and arterial stiffness are not increased in patients with milder forms of primary aldosteronism compared to patients with essential hypertension[J]. Horm Metab Res, 2021, 53(3): 178-184. |
| [25] | Choudhary MK, V?rri E, Matikainen N, et al. Primary aldosteronism: higher volume load, cardiac output and arterial stiffness than in essential hypertension[J]. J Intern Med, 2021, 289(1): 29-41. |
| [26] | Pimenta E, Gordon RD, Ahmed AH, et al. Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism[J]. J Clin Endocrinol Metab, 2011, 96(9): 2813-2820. |
| [27] | Huang X, Yu S, Xiao H, et al. Comparison of clinical features between primary aldosteronism and essential hypertension in Chinese patients[J]. Int J Endocrinol, 2021, 2021: 6685469. |
| [28] | Wu Q, Hong M, Xu J, et al. Diurnal blood pressure pattern and cardiac damage in hypertensive patients with primary aldosteronism[J]. Endocrine, 2021, 72(3): 835-843. |
| [29] | Wachtel H, Cerullo I, Bartlett EK, et al. Long-term blood pressure control in patients undergoing adrenalectomy for primary hyperaldosteronism[J]. Surgery, 2014, 156(6): 1394-1402. |
| [30] | Ahmed S, Hundemer GL. Benefits of surgical over medical treatment for unilateral primary aldosteronism[J]. Front Endocrinol (Lausanne), 2022, 13: 861581. |
| [31] | Satoh F, Ito S, Itoh H, et al. Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism[J]. Hypertens Res, 2020, 44(4): 464-472. |
| [32] | Rakugi H, Ito S, Itoh H, et al. Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension[J]. Hypertens Res, 2019, 42(12): 1932-1941. |
| [33] | Ravid JD, Laffin LJ. Effects of finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, on cardiovascular disease, chronic kidney disease, and blood pressure[J]. Curr Cardiol Rep, 2022, 24(10): 1251-1259. |
| [34] | Hundemer GL, Curhan GC, Yozamp N, et al. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism[J]. Lancet Diabetes Endocrinol, 2018, 6(1): 51-59. |
| [35] | Nomura M, Kurihara I, Itoh H, et al. Association of cardiovascular disease risk and changes in renin levels by mineralocorticoid receptor antagonists in patients with primary aldosteronism[J]. Hypertens Res, 2022, 45(9): 1476-1485. |
| [36] | Kallistratos MS, Pittaras A, Theodoulidis I, et al. Adverse effects of mineralocorticoid receptor antagonist administration[J]. Curr Pharm Des, 2018, 24(46): 5537-5541. |
/
| 〈 |
|
〉 |
